These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35231990)

  • 21. Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
    Bomsztyk J; Ravichandran S; Khwaja J; Cohen O; Rauf MU; Foard D; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore J; Lachmann H; Mahmood S; Wechalekar AD
    Br J Haematol; 2024 Jul; 205(1):138-145. PubMed ID: 38840512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
    Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
    Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
    Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
    Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
    [No Abstract]   [Full Text] [Related]  

  • 24. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab.
    Bellofiore C; Palladini G; Milani P
    Curr Oncol Rep; 2024 Sep; 26(9):1097-1103. PubMed ID: 38896184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
    Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
    Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
    Kaufman GP; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood; 2017 Aug; 130(7):900-902. PubMed ID: 28615223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
    Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
    Dima D; Hughes M; Orland M; Ullah F; Goel U; Anwer F; Raza S; Mazzoni S; Bhutani D; Williams L; Lentzsch S; Samaras C; Valent J; Chakraborty R; Khouri J
    Amyloid; 2024 Sep; 31(3):195-201. PubMed ID: 38956891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
    Hassan H; Anwer F; Javaid A; Hashmi H
    Crit Rev Oncol Hematol; 2021 Sep; 165():103435. PubMed ID: 34343658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
    Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and safety analysis of a combination regimen with BCL-2 inhibitor in relapsed/refractory primary systemic light chain amyloidosis with t(11;14) from a single center].
    Zhai AL; Liu Y; Peng N; Gong LZ; Dou XL; Wen L; Lu J
    Zhonghua Nei Ke Za Zhi; 2023 Nov; 62(11):1323-1328. PubMed ID: 37935499
    [No Abstract]   [Full Text] [Related]  

  • 35. Response matters in light chain amyloidosis, whatever it takes.
    Palladini G; Milani P
    Br J Haematol; 2024 Jul; 205(1):25-27. PubMed ID: 38842142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of efficacy and safety of daratumumab-containing regimen in relapsed and refractory multiple myeloma patients].
    Yu QR; Zhou X; Wu HY; Hao LM; Li XM; Zhong YP
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):521-525. PubMed ID: 38317364
    [No Abstract]   [Full Text] [Related]  

  • 37. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
    Minnema MC; Dispenzieri A; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Grogan M; Witteles R; Ruberg FL; Maurer MS; Tran N; Qin X; Vasey SY; Weiss BM; Vermeulen J; Jaccard A
    JACC CardioOncol; 2022 Nov; 4(4):474-487. PubMed ID: 36444227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
    Oubari S; Naser E; Papathanasiou M; Luedike P; Hagenacker T; Thimm A; Rischpler C; Kessler L; Kimmich C; Hegenbart U; Schönland S; Rassaf T; Reinhardt HC; Jöckel KH; Dürig J; Dührsen U; Carpinteiro A
    Eur J Haematol; 2021 Oct; 107(4):449-457. PubMed ID: 34185342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.
    Lentzsch S; Lagos GG; Comenzo RL; Zonder JA; Osman K; Pan S; Bhutani D; Pregja S; Sanchorawala V; Landau H
    J Clin Oncol; 2020 May; 38(13):1455-1462. PubMed ID: 32083996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.